Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (196)
  2. Journal Article (66)
  3. Review (14)
  4. Research Letter (9)
  5. Correspondence (4)
  6. Editorial (4)
  7. Guidelines (2)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (143)
  2. Department of Medicine (142)
  3. Center for Hematologic Malignancies (139)
  4. Myeloma (131)
  5. Graduate Medical Education (129)
  6. GME, Medicine (120)

More Groups

People
  1. Alexander Lesokhin (114)
  2. Kylee Maclachlan (109)
  3. Sham Mailankody (99)
  4. Urvi Shah (99)
  5. Carlyn Rose Tan (93)
  6. Malin Hultcrantz (91)

More People

Years
  1. 2025 (15)
  2. 2024 (75)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (86)
  2. Clinical Lymphoma, Myeloma and Leukemia (79)
  3. Journal of Clinical Oncology (30)
  4. Blood Cancer Journal (14)
  5. Blood Advances (13)
  6. Oncology Research and Treatment (7)

More Publications

Publishers
  1. American Society of Hematology (99)
  2. Elsevier Inc. (91)
  3. American Society of Clinical Oncology (30)
  4. Nature Publishing Group (20)
  5. Elsevier Science, Inc. (10)
  6. S. Karger AG (7)

More Publishers

Results (296)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • T-cell engagers will beat CART cell therapies in RRMM
    Meeting Abstract

    Usmani, S.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • CART cell +/- maintenance will replace auto-SCT in NDMM
    Meeting Abstract

    Usmani, S.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b–2, open-label study
    Journal Article

    Martin, T.; Lin, Y.; Agha, M.; Cohen, A. D.; Htut, M.; Stewart, A. K.; Hari, P.; Berdeja, J. G.; Usmani, S. Z.; Yeh, T. M.; more...
    The Lancet Haematology (2022)

    Fulltext@MSK | Save
  • DREAMM-9: Phase I studie von belantamab mafodotin mit standard of care bei nicht transplantationsfähigen patienten mit neu diagnostiziertem multiplem myelom
    Meeting Abstract

    Raab, M. S.; Usmani, S. Z.; Mielnik, M.; Koh, Y.; Alonso, A. A.; Leleu, X.; Quach, H.; Min, C. K.; Janowski, W.; Abdallah, A. O.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Daratumumab in kombination mit bortezomib plus dexamethason oder lenalidomid plus dexamethason im rezidivierten oder refraktären multiplen myelom: Phase 3 CASTOR und POLLUX subgruppenanalysen bei patienten mit frühem oder späten rezidiv nach initialer therapie
    Meeting Abstract

    Goldschmidt, H.; Spencer, A.; Moreau, P.; Mateos, M. V.; Suzuki, K.; Levin, M. D.; Sonneveld, P.; Yoon, S. S.; Usmani, S. Z.; Weisel, K.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Schnelligkeit und dauer des ansprechens sowie patientenberichtete endpunkte (PROs) bei der therapie mit daratumumab plus lenalidomid und dexamethason vs lenalidomid und dexamethason bei nicht-transplantablen patienten mit neu diagnostiziertem multiplen myelom: Phase 3 MAIA studie
    Meeting Abstract

    Goldschmidt, H.; Facon, T.; Kumar, S. K.; Plesner, T.; Moreau, P.; Bahlis, N.; O'Dwyer, M.; Perrot, A.; Venner, C. P.; Weisel, K.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI
    Meeting Abstract

    Usmani, S. Z.; Martin, T. G.; Berdeja, J. G.; Jakubowiak, A. J.; Agha, M. E.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A. M.; Munshi, N. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211)
    Meeting Abstract

    Usmani, S. Z.; Hoering, A.; Ailawadhi, S.; Sexton, R.; Lipe, B.; Valent, J. N.; Rosenzweig, M. A.; Zonder, J. A.; Dhodapkar, M. V.; Callander, N. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save